KCTD15 (Potassium Channel Tetramerization Domain-Containing 15) was identified as an obesity-associated gene through large-scale genome-wide association studies. The rs29941 variant sits in an intergenic region on chromosome 19 near KCTD15, and the G allele has been consistently associated with modestly increased BMI and obesity risk across multiple populations.

The Mechanism

KCTD15 is a member of the KCTD protein family that shares a common BTB domain¹¹ BTB domain
Bric-a-brac, Tramtrack, Broad complex domain — a protein-protein interaction motif at its N-terminal. The protein acts as a potent inhibitor of AP-2 transcription factors²² AP-2 transcription factors
Activating Protein 2, critical regulators of neural crest development and adipocyte differentiation. By binding directly to the activation domain of AP-2alpha, KCTD15 blocks its function in the neural crest induction hierarchy and in adipogenesis pathways.

AP-2alpha regulates the activity of C/EBPalpha³³ C/EBPalpha
CCAAT/enhancer-binding protein alpha, a master regulator of fat cell differentiation during adipogenesis. KCTD15 also interacts with GRP78⁴⁴ GRP78
glucose-regulated protein 78, an endoplasmic reticulum chaperone essential for adipogenesis across all phases of fat cell differentiation. Reduced KCTD15 activity may therefore promote excess adipogenesis and fat accumulation.

Additionally, KCTD15 attenuates the Wnt/beta-catenin signaling pathway⁵⁵ Wnt/beta-catenin signaling pathway
a key developmental pathway that also regulates adipocyte precursor commitment, further connecting it to fat tissue development.

The Evidence

The GIANT consortium meta-analysis⁶⁶ GIANT consortium meta-analysis
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009 of more than 32,000 individuals first identified KCTD15 as a genome-wide significant BMI locus (P < 5 x 10^-8). This was confirmed in an expanded analysis of 249,796 individuals⁷⁷ expanded analysis of 249,796 individuals
Speliotes et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010.

In a study of 18,014 middle-aged Danes⁸⁸ study of 18,014 middle-aged Danes
Haupt et al. Studies of metabolic phenotypic correlates of 15 obesity associated gene variants. PLoS ONE, 2011, the G allele at rs29941 was associated with per-allele odds ratios of 1.15-1.20 for overweight and 1.41-1.46 for morbid obesity. The per-allele effect on BMI is approximately 0.06-0.07 kg/m² — modest individually but meaningful in combination with other obesity variants.

The association has been replicated in East Asian populations⁹⁹ replicated in East Asian populations
Ng et al. Implication of genetic variants near obesity loci with obesity and type 2 diabetes in 7,705 Chinese. J Clin Endocrinol Metab, 2010, though allele frequencies differ substantially (G allele: ~82% in Africans, ~68% in Europeans, ~24% in East Asians).

Practical Actions

As a common GWAS hit with a modest per-allele effect, this variant represents one piece of a larger genetic obesity risk profile. Carriers of the GG genotype should focus on strategies that specifically counter enhanced adipogenesis — targeting pathways that limit new fat cell formation rather than relying on generic advice.

Interactions

KCTD15 rs29941 contributes to polygenic obesity risk alongside FTO rs9939609, MC4R rs17782313, MTCH2 rs10838738, and ETV5 rs7647305. Genetic risk score analyses show that carrying risk alleles at multiple loci has a cumulative effect on BMI — individuals in the top decile of combined risk carry approximately 2-3 kg/m² higher BMI than those in the bottom decile. The KCTD15 adipogenesis pathway is mechanistically distinct from the FTO thermogenesis and MC4R appetite-regulation pathways, meaning their effects compound rather than overlap.

CTLA-4 (Cytotoxic T-Lymphocyte Associated protein 4) is a critical immune checkpoint molecule¹¹ molecule
CTLA-4 is expressed on activated T cells and functions as a negative regulator, preventing overactive immune responses that acts as a brake on the immune system. The CT60 variant (rs3087243), located in the 3' untranslated region of the CTLA4 gene²² of the CTLA4 gene
The 3'UTR region contains regulatory sequences that control mRNA stability and translation efficiency, is one of the most extensively studied autoimmune susceptibility variants. This single nucleotide change from A to G has profound implications for immune regulation and autoimmune disease risk.

The Mechanism

The CT60 variant sits in the 3'UTR of the CTLA4 mRNA, a region that doesn't code for protein but critically controls gene expression. The G allele is in strong linkage disequilibrium with an (AT)n dinucleotide repeat³³ with an (AT)n dinucleotide repeat
Longer (AT)n repeats are associated with the G allele and reduce CTLA4 mRNA stability in the same region. Research has shown that the length of this repeat inversely correlates with both CTLA4 mRNA and protein levels in autoreactive T-cell lines. When T cells carry longer (AT)n repeats linked to the G allele, they produce less CTLA-4 protein — the molecular brake on immune activation becomes weaker.

The 3'UTR sequence affects both mRNA stability and translational efficiency⁴⁴ The 3'UTR sequence affects both mRNA stability and translational efficiency
Studies using reporter gene assays demonstrated that the CTLA4 3'UTR can confer instability to mRNA and reduce protein expression in vitro. Additionally, the variant influences the ratio of full-length CTLA-4 (bound to cell membranes) to soluble CTLA-4 (circulating in blood), with the GG genotype associated with lower production of the soluble immunoregulatory form.

The Evidence

The association between rs3087243 and autoimmune disease is supported by extensive research across multiple conditions:

Graves' Disease and Autoimmune Thyroid Disease: A case-control study of 288 Graves' disease patients⁵⁵ case-control study of 288 Graves' disease patients
The G/G genotype frequency was 70.1% in cases vs 51.4% in controls found the GG genotype conferred an odds ratio of 2.22 (95% CI: 1.58-3.13) for disease. A comprehensive meta-analysis of 20 studies⁶⁶ comprehensive meta-analysis of 20 studies
Analysis included both Graves' disease and Hashimoto's thyroiditis across Asian and Caucasian populations confirmed that CT60 polymorphism confers susceptibility to autoimmune thyroid diseases, with the G allele consistently associated with increased risk across ethnicities.

Type 1 Diabetes: The variant's role in type 1 diabetes is particularly notable in individuals who also develop thyroid autoimmunity. In a study of 4,364 type 1 diabetic patients⁷⁷ study of 4,364 type 1 diabetic patients
10.6% had thyroid peroxidase autoantibodies (TPOAbs), those with TPOAbs showed a significantly stronger association with rs3087243 (OR = 1.49 for G allele) compared to TPOAbs-negative patients (OR = 1.16). This subgroup also had a 1.94:1 female-to-male ratio compared to 0.94:1 in those without thyroid autoimmunity.

Latent Autoimmune Diabetes in Adults (LADA): A meta-analysis of 820 LADA cases⁸⁸ meta-analysis of 820 LADA cases
Analysis included 4,824 controls across multiple ethnic groups identified significant associations with LADA, particularly in Caucasian populations under a recessive model, suggesting two copies of the risk allele substantially increase susceptibility.

Rheumatoid Arthritis: A large meta-analysis of 66 studies⁹⁹ large meta-analysis of 66 studies
Included 21,681 RA patients and 23,457 controls found that A allele carriers had approximately 13% reduced risk compared to G allele carriers, with the AA genotype showing 20% reduced risk compared to GG. This means the G allele is also the risk allele for RA, consistent with its role in other autoimmune conditions, though the effect size is smaller than for thyroid disease.

Practical Implications

If you carry one or two G alleles at rs3087243, your immune system's "off switch" may be less effective. This doesn't mean you'll develop autoimmune disease — most carriers never do — but it does mean your T cells are more prone to activation and potentially more likely to attack your own tissues under the right (or wrong) environmental triggers.

The clinical significance varies by which autoimmune conditions run in your family. If you have relatives with thyroid disease, type 1 diabetes, or other autoimmune conditions, the G allele may be particularly relevant to monitor. Women with the GG genotype who also have type 1 diabetes should be especially vigilant about thyroid function, as this combination strongly predisposes to autoimmune thyroid disease.

For those with established autoimmune conditions, understanding your CTLA4 genotype may eventually inform treatment decisions. CTLA-4 is the target of checkpoint inhibitor immunotherapies¹⁰¹⁰ CTLA-4 is the target of checkpoint inhibitor immunotherapies
Drugs like ipilimumab block CTLA-4 to enhance immune responses against cancer used in cancer treatment, and genetic variation at this locus may predict both therapeutic response and immune-related adverse events.

Interactions

CTLA4 rs3087243 interacts with other immune-regulatory variants to modulate autoimmune risk. The most notable interaction is with rs231775 (+49A/G)¹¹¹¹ rs231775 (+49A/G)
This exon 1 variant causes a threonine-to-alanine amino acid change affecting CTLA-4 glycosylation, also in the CTLA4 gene, which affects CTLA-4 protein folding and cell surface expression. Individuals carrying risk alleles at both positions show enhanced susceptibility to Graves' disease and type 1 diabetes compared to either variant alone.

The variant also shows epistatic interactions with PTPN22 rs2476601 (another T-cell regulatory gene variant) in determining autoimmune disease risk. Evidence suggests genetic interaction between HLA class II genotypes and rs3087243 in type 1 diabetes¹²¹² Evidence suggests genetic interaction between HLA class II genotypes and rs3087243 in type 1 diabetes
Combined effects were observed beyond simple additive models, indicating that autoimmune susceptibility emerges from complex networks of immune gene variants rather than single mutations.

Vitamin C cannot be made by the human body. Every microgram of ascorbate¹¹ ascorbate
The biologically active, ionized form of ascorbic acid at physiological pH in your blood got there by being eaten and then actively transported across your intestinal lining and conserved by your kidneys. The gene SLC23A1 encodes SVCT1²² SVCT1
Sodium-dependent Vitamin C Transporter 1 — a 12-transmembrane-domain protein expressed on the apical surface of intestinal and kidney epithelial cells, the transporter protein responsible for both of these steps. A single nucleotide change at position 264 swaps valine for methionine in the transporter, reducing its efficiency and measurably lowering circulating vitamin C levels.

The Mechanism

SVCT1 is an apical membrane³³ apical membrane
The cell surface facing the intestinal lumen or kidney tubule, where nutrients are absorbed from transporter that uses the sodium gradient to drive ascorbic acid into intestinal epithelial cells and kidney tubule cells. In the intestine it mediates dietary vitamin C absorption; in the kidney it reclaims filtered ascorbate before it can be lost in urine. The Val264Met substitution occurs in the protein's core transmembrane region, likely altering the conformational changes needed for the transport cycle. In vitro studies show the variant transporter moves ascorbate at roughly 40-50% reduced capacity⁴⁴ 40-50% reduced capacity
Eck P et al. Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1-SVCT1. Genes Nutr, 2007 compared to the wild-type protein.

Knockout mouse studies⁵⁵ Knockout mouse studies
Corpe CP et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest, 2010 dramatically illustrate SVCT1's importance: mice completely lacking Slc23a1 excrete 18 times more ascorbate in their urine, and 45% of pups die perinatally from vitamin C depletion. Humans carrying Val264Met have a far milder effect — they still absorb and reabsorb vitamin C, just less efficiently.

The Evidence

The definitive human study is a meta-analysis of five independent UK cohorts⁶⁶ meta-analysis of five independent UK cohorts
Timpson NJ et al. Genetic variation at the SLC23A1 locus is associated with circulating concentrations of L-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr, 2010 totaling 15,087 participants. Each copy of the T allele was associated with a 5.98 umol/L reduction in plasma vitamin C (95% CI: -8.23 to -3.73; P = 2.0 x 10^-7). Heterozygotes had roughly 24% lower plasma vitamin C than homozygous normal individuals. The effect was consistent across all five cohorts, ranging from -4.15 umol/L in the discovery cohort to -8.31 umol/L in the EPIC-Norfolk study.

For context, adequate plasma vitamin C is generally considered to be above 28 umol/L, with levels below 11 umol/L indicating deficiency. A reduction of ~6 umol/L per allele is clinically meaningful in people whose dietary intake is already marginal — it can push borderline-adequate levels into the insufficient range.

The variant has also been used as a genetic instrument in Mendelian randomization studies⁷⁷ Mendelian randomization studies
Wade KH et al. Variation in the SLC23A1 gene does not influence cardiometabolic outcomes to the extent expected given its association with L-ascorbic acid. Am J Clin Nutr, 2015 to test whether vitamin C causally protects against cardiovascular disease. Despite strong observational correlations between higher vitamin C and better cardiometabolic profiles, the genetic evidence showed no causal relationship — the observational associations are likely due to confounding (people who eat more fruit and vegetables tend to be healthier overall). A similar Mendelian randomization in 106,147 individuals⁸⁸ 106,147 individuals
Kobylecki CJ et al. Genetically high plasma vitamin C and urate: a Mendelian randomization study. Rheumatology, 2018 found no causal link between genetically determined vitamin C levels and plasma urate or gout risk.

Practical Implications

The Val264Met variant is relatively rare — only about 3-4% of Europeans carry one copy, and homozygotes are extremely uncommon (<0.5%). Among people of African descent the T allele is somewhat more common (~6%), while it is rarer in East Asian (~1.2%) and South Asian (~1.5%) populations.

For carriers, the key takeaway is straightforward: your body is less efficient at absorbing and retaining vitamin C, so you may need to be more intentional about intake. This does not mean megadosing — vitamin C absorption has a saturation ceiling regardless of genotype. It means ensuring you consistently get enough through diet (citrus, berries, bell peppers, broccoli, kiwi) or a modest daily supplement (200-500 mg ascorbic acid), and being aware that your baseline plasma levels will run lower than someone with the same diet but normal SVCT1 function.

Smokers and people with high oxidative stress should pay particular attention, since smoking independently lowers vitamin C levels. If you carry this variant and smoke, or have a diet low in fruits and vegetables, your plasma ascorbate may dip into the deficiency range.

Interactions

SLC23A1 works alongside SLC23A2⁹⁹ SLC23A2
Encodes SVCT2, a vitamin C transporter expressed in metabolically active tissues (brain, adrenals, eyes). Unlike SVCT1, which controls whole-body homeostasis, SVCT2 handles local tissue-level vitamin C delivery, which encodes the tissue-level vitamin C transporter SVCT2. Variants in both transporters could theoretically compound the effect on vitamin C status, though this specific interaction has not been well studied. In the EPIC cohort, both rs33972313 (SLC23A1) and SLC23A2 variants (rs6053005, rs6133175) independently predicted plasma vitamin C levels, suggesting additive effects on vitamin C homeostasis.

TRAF3IP2 encodes Act1 (also called CIKS — connector of kinase to stress-activated protein kinase), the essential adaptor protein¹¹ essential adaptor protein
Act1 is recruited to the cytoplasmic domain of the IL-17 receptor complex upon IL-17A or IL-17F binding that bridges IL-17 receptor activation to downstream inflammatory gene expression. When IL-17 binds its receptor on keratinocytes, fibroblasts, and mucosal epithelial cells, Act1 assembles a signaling scaffold that recruits TRAF6 and ultimately activates NF-κB — the master switch for pro-inflammatory cytokines including IL-6, IL-8, CXCL1, and GM-CSF. The D10N variant disrupts this scaffold at its very foundation, producing consequences that are paradoxical and clinically important.

The Mechanism

Aspartic acid at position 10 of Act1 is required for two critical interactions: binding to the molecular chaperone Hsp90²² binding to the molecular chaperone Hsp90
Act1 is an obligate client protein of Hsp90; the chaperone stabilizes Act1 and directs its proper folding and activity, and binding to TRAF6, TRAF2, and TRAF3. The D10N substitution (aspartic acid → asparagine, a conservative but chemically critical change) abolishes both interactions simultaneously.

Without Hsp90 regulation, D10N Act1 loses its ability to engage any known IL-17 signaling component³³ D10N Act1 loses its ability to engage any known IL-17 signaling component
D10N-reconstituted Act1-deficient cells fail to activate IκBα phosphorylation, Erk/Jnk, or NF-κB upon IL-17 stimulation — it cannot bind IL-17 receptor, TRAF6, TRAF2, TRAF3, or IKKi. Functional assays demonstrated near-complete disruption of TRAF6 binding⁴⁴ near-complete disruption of TRAF6 binding
Full-length TRAF3IP2 construct containing D10N showed a nearly completely disrupted interaction with TRAF6 compared to wild-type Act1, making it effectively a loss-of-function allele in the IL-17 pathway.

The paradox: losing IL-17 signaling through Act1 should dampen inflammation. Instead, Act1-null mice develop spontaneous skin inflammation driven by IL-22⁵⁵ Act1-null mice develop spontaneous skin inflammation driven by IL-22
In the absence of IL-17-mediated signaling, IL-22 becomes the dominant inflammatory cytokine and T-cell-intrinsic Act1 loss causes hyper-Th17 responses. IL-17 signaling normally provides a negative feedback on Th17 cell expansion. When Act1 is non-functional, this brake is removed, Th17 cells proliferate excessively, and IL-22-driven keratinocyte hyperproliferation — the hallmark of psoriatic plaques — ensues.

The Evidence

Two independent genome-wide association studies published simultaneously in 2010 established TRAF3IP2 as a major psoriasis susceptibility locus. The coding variant rs33980500 showed combined P=1.13×10⁻²⁰ with OR=1.95⁶⁶ combined P=1.13×10⁻²⁰ with OR=1.95
Discovery cohort of 609 German PsA cases plus replication in 6 European cohorts totaling 5,488 individuals — one of the strongest non-HLA associations in psoriasis genetics. A concurrent GWAS⁷⁷ concurrent GWAS
Independent US/Canadian cohort with 6,487 cases and 8,037 controls, combined P=1.24×10⁻¹⁶ confirmed the association, with OR for psoriatic arthritis reaching 1.57 (95% CI 1.38–1.78).

The T risk allele shows marked ancestry stratification⁸⁸ marked ancestry stratification
Variant absent in Han Chinese; frequency ~7.4% European, ~14.2% African, ~1.1% East Asian: common in European and African populations but nearly absent in East Asian populations, where psoriasis has a different genetic architecture. This population difference explains why TRAF3IP2 associations were discovered in European cohorts.

Neutrophil extracellular traps (NETs) — DNA-protein webs released by activated neutrophils⁹⁹ Neutrophil extracellular traps (NETs) — DNA-protein webs released by activated neutrophils
NETs are abundant in psoriatic lesions and known to trigger Th17 differentiation via TLR2 and TLR4 activation interact with D10N genotype in a dose-dependent manner: in the presence of spontaneous NETs, both Th17 percentages and IL-17A release were significantly more pronounced in D10N homozygotes than wild-type, linking innate immune triggers specifically to the D10N genotype.

Practical Implications

The D10N variant has two clinical dimensions: disease susceptibility and treatment pharmacogenomics.

For disease risk, T allele carriers have 1.3-fold (heterozygous) to 1.95-fold (homozygous) elevated baseline risk for psoriasis vulgaris and psoriatic arthritis. The variant predisposes to the IL-22-driven keratinocyte proliferation and plaque formation characteristic of psoriasis. Psoriasis triggers — skin trauma (Koebner phenomenon), streptococcal infections, certain medications (beta-blockers, lithium, antimalarials), and obesity — are especially relevant for T allele carriers.

For anti-IL-17 biologic therapy (secukinumab, ixekizumab, brodalumab), the D10N variant has pharmacogenomic significance. Because these drugs block IL-17A or the IL-17 receptor, and because D10N carriers already have impaired IL-17 downstream signaling, the therapeutic pathway is partially pre-disrupted. One pharmacogenomic analysis found that TRAF3IP2_v1 allele absence was associated with better secukinumab response¹⁰¹⁰ TRAF3IP2_v1 allele absence was associated with better secukinumab response
HLA-Cw6+ patients responded significantly better to secukinumab depending on TRAF3IP2_v1 allele absence in HLA-Cw6+ patients. For TNF-inhibitor therapy¹¹¹¹ TNF-inhibitor therapy
163 PsA patients; TRAF3IP2 variant allele carriers showed better DAPsA score improvement on TNF-inhibitors at 22 and 54 weeks, suggesting the variant modifies biologic treatment response, D10N carriers showed improved joint inflammation outcomes.

Psoriatic skin, when present, should be evaluated for joint involvement (psoriatic arthritis affects ~30% of psoriasis patients); early detection matters because joint damage is progressive.

Interactions

The TRAF3IP2 D10N variant operates within the broader IL-17/Th17 pathway where multiple genetic loci converge. rs12191877 (HLA-C*06:02), the strongest psoriasis susceptibility variant, primarily affects T-cell recognition of self-antigens and is the main predictor of biologic response (especially ustekinumab). The combination of HLA-C*06:02 with TRAF3IP2 D10N creates a dual-hit: impaired immune tolerance (HLA) plus enhanced Th17 expansion with IL-22 skew (TRAF3IP2).

rs12188300 (IL12B) affects upstream Th17 differentiation through IL-12/IL-23 signaling. IL-23 drives Th17 commitment; when TRAF3IP2 D10N then removes the IL-17-dependent negative feedback on Th17 cells, the combination of enhanced Th17 differentiation (IL12B) and unregulated Th17 expansion (TRAF3IP2) may substantially amplify psoriasis susceptibility and plaque severity.

A compound action examining the interaction between rs33980500-T and rs12191877-T (HLA-C*06:02) would be appropriate: both genotypes should co-occur in the same individual for consideration of early dermatology referral and monitoring for biologic therapy eligibility, given substantially elevated combined psoriasis risk and pharmacogenomically relevant anti-IL-17 response modification.

The lymphotoxin beta receptor (LTBR)¹¹ lymphotoxin beta receptor (LTBR)
A member of the TNF receptor superfamily encoded on chromosome 12p13.31; binds lymphotoxin-α1β2 and the LIGHT cytokine is a critical organizer of secondary lymphoid tissue architecture and innate immune tone. rs3758524 is a regulatory intronic variant associated with altered LTBR expression. Carriers of the minor A allele may have reduced LTBR signaling output — a change with consequences for how the immune system organizes lymphoid structures and mounts defenses against intracellular pathogens.

The A allele is rare across all populations, occurring in roughly 1–5% of individuals globally, with higher frequencies observed in East Asian populations (approximately 2–5%) compared to Europeans (~1%) or Africans (~1%). Most people carry the common GG genotype.

The Mechanism

LTBR sits at the hub of a dual NF-κB signaling network. When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex²² When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex
This leads to rapid degradation of IκBα and transient activation of RelA:p50 dimers, producing an acute inflammatory response. In parallel, LTBR triggers the alternative (non-canonical) NF-κB pathway³³ alternative (non-canonical) NF-κB pathway
This pathway uses NIK (NF-κB-inducing kinase) and IKKα to process p100 into p52, generating sustained RelB:p52 complexes that drive lymphoid organogenic genes. These two pathways operate independently and are not redundant — together, they shape chemokine gradients, follicular dendritic cell maturation, and stromal cell function in lymph nodes and spleen.

Regulatory variants that reduce LTBR expression dampen both arms of this response⁴⁴ Regulatory variants that reduce LTBR expression dampen both arms of this response
Reduced surface receptor density means less signal transduction per ligand-binding event, blunting both the acute RelA response and the sustained RelB organogenic response. The net effect is subtly impaired lymphoid tissue organization and reduced innate capacity to respond to certain pathogens.

The Evidence

LTBR's role in infection defense is most directly established in mycobacterial models. Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)⁵⁵ Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)
A soluble LTβR-IgG1 fusion protein was used to block signaling. Critically, the LTBR and TNF receptor pathways are non-redundant⁶⁶ non-redundant
Blocking both simultaneously caused extensive splenic necrosis — neither compensates for the other.

For the specific rsid, direct human genetic association data is limited. However, the broader LTBR variant literature provides biological grounding. A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers⁷⁷ A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers
GT genotype: 38.4% in resolvers vs 22.2% in chronically infected patients (p = 0.004), suggesting that genetic differences in LTBR function modulate viral infection outcomes. LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children⁸⁸ LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children
rs3759334 dominant model p = 0.017; rs2364480 allele p = 0.041, implicating LTBR in immune-complex-mediated inflammatory disease susceptibility.

In the context of juvenile idiopathic arthritis and systemic sclerosis, LTBR pathway activity influences tertiary lymphoid structure (TLS) formation at inflamed joints and fibrotic tissues — a mechanism under active investigation. The evidence base for rs3758524 specifically is emerging, with no large-scale genetic association studies published to date.

Practical Implications

Carriers of the A allele face a modestly altered baseline of LTBR-mediated immune signaling. The main practical concerns are in two areas: susceptibility to certain intracellular pathogens that rely on granuloma-mediated containment, and potentially altered risk of inflammatory conditions where tertiary lymphoid structures shape disease chronicity. Given the rarity of the A allele and the emerging state of the evidence, the actionable focus is on monitoring and early intervention for infections rather than any specific preventive supplement or avoidance.

Interactions

LTBR signaling interacts functionally with the TNF receptor pathway (TNFR1/TNFR2), and these pathways show additive rather than redundant effects in controlling intracellular infections. LTBR-driven alternative NF-κB also intersects with LIGHT/HVEM signaling (TNFRSF14, rs1886730), which shares ligands and downstream targets. Variants in the classical NF-κB arm (RELA, NFKB1) could modulate how much compensation occurs when LTBR signaling is reduced.

Endometriosis — in which tissue resembling the uterine lining grows outside the uterus — affects approximately 10% of women of reproductive age and is one of the leading causes of chronic pelvic pain and infertility. The condition is strongly heritable, yet the molecular events that allow retrograde endometrial cells to implant and survive on peritoneal surfaces remain incompletely understood. rs3820282 stands out among endometriosis risk variants because functional experiments have revealed its mechanism with unusual clarity: it creates a new binding site for the estrogen receptor¹¹ creates a new binding site for the estrogen receptor
ESR1: estrogen receptor alpha, a transcription factor that mediates the downstream effects of estrogen on gene expression directly within the first intron of WNT4, converting what was a transcriptionally quiet region into an estrogen-responsive switch.

rs3820282 lies on chromosome 1p36.12 within intron 1 of the WNT4 gene, approximately 21 kb from the widely-studied rs7521902. Although both SNPs tag the same 1p36 haplotype block and are in linkage disequilibrium²² linkage disequilibrium
LD: the tendency for nearby variants to be inherited together; variants in high LD are often proxies for the same underlying causal signal in European populations, rs3820282 has emerged from fine-mapping studies as the more direct molecular actor — the variant whose alternative allele appears to alter the DNA sequence itself rather than simply tagging a nearby causal change.

The Mechanism

WNT4 encodes a secreted glycoprotein belonging to the Wnt signaling family, which is essential for the embryonic development of the female reproductive tract from Müllerian duct precursors and for the monthly decidualization of the endometrium. The protein operates downstream of the IHH–COUPTFII pathway³³ IHH–COUPTFII pathway
the Indian Hedgehog – COUP transcription factor II axis, which coordinates progesterone response in endometrial stromal cells during the secretory phase to drive the transformation of endometrial stromal cells into specialized decidual cells — a prerequisite for embryo implantation.

The T allele at rs3820282 changes the intronic sequence from C to T, introducing a high-affinity recognition motif for estrogen receptor alpha (ERα). When estrogen levels peak before ovulation, ERα bound to this newly created site activates WNT4 transcription in the endometrial stroma, producing 1.48–3.27 log2-fold higher WNT4 expression⁴⁴ 1.48–3.27 log2-fold higher WNT4 expression
measured in CRISPR-edited knock-in mouse lines carrying the human T allele; Pavličev et al. 2024 Nature Communications during the proestrus and estrus cycle phases. The downstream effect is a uterine stromal environment with enhanced invasibility — better at accepting an implanting embryo, but also more permissive to attachment by ectopic endometrial fragments shed into the peritoneal cavity during retrograde menstruation.

This same variant simultaneously acts as an expression quantitative trait locus (eQTL)⁵⁵ expression quantitative trait locus (eQTL)
a variant that affects how much RNA is produced from a nearby gene rather than changing the protein sequence for two nearby genes: LINC00339 (a long non-coding RNA, whose expression is decreased by the risk allele) and CDC42 (a Rho GTPase involved in cytoskeletal organization and cell migration, whose expression is increased). Elevated CDC42 activity may further facilitate the migratory behavior of ectopic endometrial cells.

The Evidence

Fine-mapping of the chromosome 1p36 WNT4 region in 930 endometriosis cases and 959 controls⁶⁶ 930 endometriosis cases and 959 controls
Luong et al. Int J Mol Epidemiol Genet, 2013 identified rs3820282 as one of three variants with stronger association than the previously-reported rs7521902, noting its position within recognition motifs for both ESR1 and ESR2 — a direct prediction of the estrogen-receptor mechanism later confirmed experimentally.

In a 7,090-person fine-mapping study⁷⁷ 7,090-person fine-mapping study
Powell et al. Human Molecular Genetics, 2016 (2,594 endometriosis cases, 4,496 controls), rs3820282 showed the strongest association at the 1p36.12 locus for endometriosis (P = 1.84 × 10⁻⁵, OR = 1.244, 95% CI 1.126–1.375), outperforming rs7521902 as a direct disease signal. The same variant was confirmed as an eQTL for both LINC00339 and CDC42 in endometrial tissue.

The functional confirmation arrived in 2024: CRISPR knock-in experiments⁸⁸ CRISPR knock-in experiments
Pavličev et al. Nature Communications, 2024 in mice introduced the human T allele into the equivalent Wnt4 locus. Both independently generated knock-in lines showed significantly higher uterine Wnt4 expression compared to wildtype animals during the estrogen-peak phases (proestrus and estrus), confirming the estrogen-receptor-binding mechanism proposed from human sequence analysis.

A striking feature of rs3820282 is antagonistic pleiotropy across reproductive tissues. The same T allele that raises endometriosis and fibroid risk appears to confer reproductive benefit: across multiple GWAS, the T allele is associated with longer gestation and reduced preterm birth risk. Conversely, the C allele — which is relatively rare in East Asian populations — is the risk allele for pelvic organ prolapse⁹⁹ pelvic organ prolapse
a condition in which the pelvic floor structures weaken and pelvic organs descend into the vaginal canal (OR 1.18, P = 3 × 10⁻²¹). This explains why the T allele has remained common despite its association with endometriosis: in evolutionary terms, the same molecular mechanism that facilitates embryo implantation comes at the cost of ectopic endometrial invasion.

Practical Implications

For women carrying one or two copies of the T allele, the most actionable implication is awareness of endometriosis symptoms and a lower threshold for seeking specialist evaluation rather than accepting menstrual pain as normal. The average diagnostic delay for endometriosis is 4–11 years from first symptoms, driven by normalization of dysmenorrhea and the requirement for laparoscopic confirmation.

The WNT4 locus is also associated with uterine fibroids (leiomyomas) at genome-wide significance. T allele carriers may therefore warrant gynecological evaluation that includes assessment for both conditions — a pelvic ultrasound can screen for both ovarian endometriomas and uterine fibroid burden simultaneously.

No supplement or dietary intervention specifically targeting the estrogen-receptor-WNT4 axis has been studied. Progestin-based hormonal therapies remain the mainstay of endometriosis management and address the progesterone-resistance pathway through which WNT4 dysregulation is thought to act.

Interactions

rs7521902 (WNT4 1p36.12 sentinel): rs7521902 is in moderate-to-high linkage disequilibrium with rs3820282 in European populations, meaning both variants partly tag the same underlying haplotype signal. In populations where LD is lower (East Asian, Brazilian cohorts), rs3820282 may be the more informative marker. Users carrying risk alleles at both loci reflect the same biological signal rather than independent additive contributions.

rs4762326 (VEZT, chromosome 12q23.2): The VEZT locus encodes vezatin, a component of adherens junctions that mediates cell-cell adhesion. VEZT and WNT4 represent two mechanistically distinct pathways to ectopic endometrial implantation — cell adhesion capacity vs. estrogen-driven stromal invasibility. Carrying risk alleles at both loci could compound endometriosis susceptibility through complementary mechanisms, though formal gene-gene interaction data have not been published.

rs1250248 (FN1 — fibronectin 1): An epistatic interaction between the WNT4 locus (rs7521902) and FN1 has been described for ovarian endometriosis (OR 1.56 for the interaction term; Pagliardini et al. 2013, PMID 23142796). Fibronectin is a major extracellular matrix glycoprotein that works alongside cell adhesion receptors; it may interact directly with the WNT4-driven stromal invasibility that rs3820282 mediates.

Protein S — encoded by the PROS1 gene on chromosome 3q11.1 — is one of the body's primary anticoagulant regulators. It circulates in plasma partly free (the active anticoagulant fraction, ~40%) and partly bound to C4b-binding protein (~60%). Free protein S serves as a cofactor for activated protein C (APC)¹¹ activated protein C (APC)
APC degrades the procoagulant factors Va and VIIIa, acting as a molecular brake on the coagulation cascade, preventing excessive fibrin clot formation. Protein S can also inhibit coagulation independently of protein C by directly blocking prothrombinase and tenase complex assembly. The PROS1 Y234C variant (rs387906675) is one of the rarest and most severe single-nucleotide mutations in this gene: homozygous carriers develop protein S activity below 10%²² protein S activity below 10%
Measured in the index patient from Fischer et al., 2010; normal range is roughly 60–140% of mean reference activity, producing life-threatening neonatal thrombosis.

The Mechanism

The c.701A>G transition (plus-strand notation: T>C at rs387906675) changes tyrosine at position 234 to cysteine in the protein S polypeptide chain. Tyrosine 234 is located within the laminin G-type (LG) domain³³ laminin G-type (LG) domain
A structural domain important for protein S binding to C4b-binding protein and factor Xa; point mutations here typically disrupt both secretion and cofactor function of protein S. The introduction of a free thiol group from cysteine in this structurally constrained position disrupts protein folding, likely preventing normal secretion from hepatocytes or degrading the mature protein's ability to bind and activate protein C. The net effect is either absent or non-functional protein S — clinically indistinguishable from a null allele in terms of residual anticoagulant activity.

Heterozygous carriers produce approximately half the normal amount of functional protein S from the intact allele. This partial deficiency (typically 30–60% of normal free protein S activity) is sufficient for most everyday hemostasis but creates a measurable prothrombotic state, especially under provoking circumstances — pregnancy, oral contraceptive use, surgery, prolonged immobility, or intercurrent illness.

The Evidence

The variant was first reported by Fischer and colleagues in 2010⁴⁴ first reported by Fischer and colleagues in 2010
Neonatology 2010, 98(4):337–40; case of an Albanian-origin infant in an infant born of consanguineous parents who presented on day four of life with seizures and hemorrhagic shock. MRI revealed massive intracranial hemorrhage; coagulation studies demonstrated protein S activity below 10%. The infant subsequently developed aortic thrombosis and died on day eight. Post-mortem examination showed diffuse thromboses of intracerebral capillaries, confirming the underlying prothrombotic state produced both thrombotic and hemorrhagic pathology simultaneously — the paradox of severe thrombophilia, where occlusion of small vessels causes ischemic infarction and secondary hemorrhage upstream.

For heterozygous carriers, risk quantification comes from broader protein S deficiency cohort data. A 2025 population-scale JAMA study⁵⁵ 2025 population-scale JAMA study
UK Biobank + NIH All of Us; 600,000+ participants, 18,011 VTE events stratified PROS1 variant risk by mutation class: heterozygous carriers of missense PROS1 variants had OR 1.98 for VTE, while carriers of complete loss-of-function variants (nonsense, frameshift, essential splice site) had OR 14.01. Y234C functionally approximates a loss-of-function allele given residual protein S activity near zero, placing heterozygous carriers toward the higher end of the missense risk spectrum. A Danish family cohort⁶⁶ Danish family cohort
87 PS-deficient participants and relatives; Christensen et al. 2021 found 43% of individuals with coding PROS1 variants experienced at least one VTE, versus 17% in non-carrier family members. Prospective follow-up data estimate an annual first-VTE incidence of ~0.7% in heterozygous protein S deficiency⁷⁷ ~0.7% in heterozygous protein S deficiency
Comparable to other high-penetrance inherited thrombophilias such as protein C deficiency and antithrombin deficiency — roughly 5-fold above the population baseline. Recurrence risk after a first event is substantially higher: 6–10% per year⁸⁸ 6–10% per year.

Practical Implications

For heterozygous carriers who have not had a VTE, the priority is identifying and modifying provoking risk factors — especially estrogen-containing hormonal contraceptives, which independently increase VTE risk 3–5-fold and combine multiplicatively with inherited thrombophilias. Carrier status should be documented prominently in the medical record so that prophylaxis can be given during surgery, prolonged hospitalization, and obstetric care. Direct oral anticoagulants (DOACs — apixaban, rivaroxaban) are now preferred over vitamin K antagonists for most VTE treatment episodes; carriers whose VTE was unprovoked or recurrent should discuss whether indefinite anticoagulation is appropriate.

For homozygous carriers or compound heterozygotes (carrying Y234C on one allele and a different pathogenic PROS1 variant on the other), clinical presentation is often in the neonatal period or early infancy with purpura fulminans, multifocal thrombosis, or intracranial hemorrhage. Emergency management includes fresh frozen plasma (FFP) to restore protein S, followed by long-term anticoagulation and consideration of protein S concentrate where available.

Interactions

The most clinically significant interaction is with Factor V Leiden (rs6025, F5 R506Q)⁹⁹ Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden renders activated factor V partially resistant to inactivation by activated protein C — since protein S is the cofactor for APC, these two defects are mechanistically synergistic. A documented case of a child with protein S deficiency plus heterozygous Factor V Leiden developed neonatal purpura fulminans despite each defect being individually less severe. Similarly, compound PROS1/PROC mutations (protein S plus protein C deficiency) produce synergistic prothrombotic effects: severe PS deficiency can unmask a pathogenic PROC variant even when protein C activity appears normal by standard testing.

The prothrombin G20210A variant (rs1799963, F2) is the second most common inherited thrombophilia; in combination with protein S deficiency it compounds VTE risk in an additive fashion, justifying a complete thrombophilia panel in any carrier.

to Insulin Resistance

Polycystic ovary syndrome (PCOS) affects 5–15% of women of reproductive age worldwide and is the leading cause of anovulatory infertility. Beyond its reproductive features — irregular cycles, excess androgens, and polycystic ovaries — PCOS is fundamentally a metabolic disorder: 50–70% of affected women have insulin resistance, independent of body weight. Genome-wide association studies in Han Chinese women have identified over a dozen PCOS susceptibility loci, and among them rs4784165 near the TOX3 gene¹¹ rs4784165 near the TOX3 gene
TOX3: TOX High Mobility Group Box Family Member 3, chromosome 16q12.1 stands out for its specific link to the metabolic rather than purely hormonal features of the syndrome.

The Mechanism

TOX3²² TOX3
a high-mobility-group (HMG) box transcription factor originally characterized in neurons encodes a protein that regulates calcium-dependent gene transcription. TOX3 interacts with CREB (cAMP response element- binding protein) and CBP (CREB-binding protein), and knockdown of endogenous TOX3 substantially reduces calcium-induced gene expression. In addition to its neuronal role, emerging evidence places TOX3 in hepatic metabolic regulation: studies suggest TOX3 controls hepatic gluconeogenesis and insulin sensitivity through hepatic transcriptional programs, and that dysregulation of TOX3 exacerbates insulin resistance and glucose intolerance — mechanisms central to both type 2 diabetes and PCOS pathogenesis.

The rs4784165 variant sits in an intronic region of a long non-coding RNA locus (LOC107984901) on chromosome 16q12.1, approximately adjacent to the TOX3 gene. No pathogenic coding mutations have been found in TOX3 in PCOS women, confirming that rs4784165 acts as a regulatory signal³³ rs4784165 acts as a regulatory signal
sequencing of all TOX3 exons and exon-intron boundaries in 200 Han Chinese PCOS women found no pathogenic variants, PMID 25311971 rather than a structural variant. Epigenetic data support this interpretation: Ning et al. 2017 (30 PCOS/30 controls)⁴⁴ Ning et al. 2017 (30 PCOS/30 controls)
European Review for Medical and Pharmacological Sciences found significantly lower TOX3 promoter methylation in PCOS granular cells and serum, leading to reduced TOX3 protein expression — suggesting the variant alters local chromatin accessibility or regulatory element activity near this locus.

The Evidence

The TOX3 rs4784165 G allele was first identified as a PCOS risk allele in a second Han Chinese genome-wide association study by Shi et al. 2012⁵⁵ second Han Chinese genome-wide association study by Shi et al. 2012
Nature Genetics; 1,510 cases and 2,016 controls discovery + independent replication, one of eight newly discovered PCOS loci. The GWAS odds ratio for G allele carriers is approximately 1.15, a modest but consistently replicated effect. A meta-analysis across 47 studies (10,584 PCOS cases, 16,150 controls) estimated OR = 1.08 (95% CI: 1.00–1.16) for PCOS susceptibility.

The clinical significance of this locus extends beyond simple disease susceptibility to metabolic stratification within PCOS. Tian et al. 2020 (2,082 Han Chinese PCOS women)⁶⁶ Tian et al. 2020 (2,082 Han Chinese PCOS women)
Frontiers in Endocrinology found that women carrying at least one G allele (GG + GT) had significantly higher rates of insulin resistance than TT homozygotes (53.3% vs. 48.5%, P = 0.027, OR = 1.27) after adjustment for age and BMI — a dominant model effect. The G allele was also associated with elevated TG/HDL-C ratios, a key atherogenic marker. Across populations, the G allele frequency varies substantially: ~25% in Europeans, ~33% in East Asians, and ~42% in Africans.

In a Saudi Arabian cohort, Bakhashab & Ahmed 2019 (94 PCOS cases, 94 controls)⁷⁷ Bakhashab & Ahmed 2019 (94 PCOS cases, 94 controls)
Bioinformation found significant association between rs4784165 and the combined oligo/amenorrhea plus polycystic ovarian morphology PCOS subgroup, linking this variant to the ovarian structural features of the syndrome as well as metabolic features. Notably, replication of this locus in European populations has not been conclusively demonstrated, suggesting either ethnic-specific genetic architecture or insufficient power in available European cohorts.

Practical Actions

For G allele carriers with PCOS or PCOS-adjacent features (irregular cycles, elevated androgens, insulin resistance), the dominant model association with insulin resistance is the most actionable finding. Insulin resistance in PCOS is independently addressable through genotype-informed supplementation: myo-inositol (the glucose-transporter-linked signaling molecule) at 2–4 g/day has the strongest evidence base for improving insulin sensitivity, ovarian function, and androgen levels specifically in PCOS women with insulin resistance — effects that are more pronounced in those with documented IR at baseline.

Fasting insulin and HOMA-IR monitoring — ideally annually for GG homozygotes — provides the earliest signal of progressing insulin resistance before it affects glucose tolerance. The TG/HDL-C ratio (elevated in G allele carriers per Tian 2020) is a readily available surrogate marker for atherogenic dyslipidemia and insulin resistance that can be tracked with a standard fasting lipid panel.

Interactions

rs2479106 (DENND1A): DENND1A is the strongest GWAS-replicated PCOS locus and acts through theca cell androgen biosynthesis. TOX3 rs4784165 and DENND1A rs2479106 appear to affect PCOS through different mechanisms — androgen production vs. insulin resistance — and women carrying risk alleles at both loci may face compounding PCOS severity across both hormonal and metabolic dimensions. No compound effect study has directly examined this combination.

rs13405728 (LHCGR): The LH/hCG receptor locus affects gonadotropin sensitivity in granulosa cells. Combined risk at LHCGR (elevated LH sensitivity) and TOX3 (impaired metabolic transcriptional regulation) may represent a pathway from hypothalamic-pituitary dysregulation to ovarian dysfunction, though no published study has examined these loci jointly.

Angiotensinogen (AGT)¹¹ Angiotensinogen (AGT)
the precursor protein for the entire renin-angiotensin-aldosterone system (RAAS) is produced primarily in the liver and released into the bloodstream, where renin cleaves it to angiotensin I. Angiotensin I is then converted by ACE into angiotensin II — the potent vasoconstrictor that raises blood pressure, promotes sodium retention, and drives cardiovascular remodeling. The rs5051 (G-6A) variant sits in the core promoter of the AGT gene, just 6 base pairs upstream of the transcription start site, where it acts as a molecular volume knob for angiotensinogen production.

The Mechanism

The AGT gene sits on the minus (reverse) strand of chromosome 1. In minus-strand notation, the variant is described as G-6A: a guanine-to-adenine substitution at position −6 relative to the transcription start. On the sequencing plus strand (what genome files report), this corresponds to a C-to-T change at rs5051.

The −6 position lies within the core promoter where transcription factors assemble to initiate RNA synthesis. Luciferase reporter assays²² Luciferase reporter assays
a standard molecular technique measuring how powerfully a DNA sequence drives gene expression demonstrate that the A allele at −6 (plus-strand T) drives significantly higher AGT transcriptional activity than the G allele — up to 68.6% more mRNA output³³ up to 68.6% more mRNA output. The adenine at this position likely alters the binding affinity of a transcription factor at or near the core promoter, sustaining higher rates of AGT mRNA synthesis. More AGT mRNA → more angiotensinogen protein → more substrate for renin → more angiotensin I → more angiotensin II → chronically elevated blood pressure.

The Evidence

Powell et al. 2024⁴⁴ Powell et al. 2024
Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension. Chronic Dis Transl Med, 2024 analyzed 311,004 UK Biobank participants and found that rs5051 C>T associates with a 0.35 mmHg increase in systolic blood pressure per T allele (p<0.001). The effect was fourfold larger in Black participants (1.17 mmHg per allele, p=0.032) than in White participants (0.25 mmHg), consistent with the T allele's much higher frequency in African-ancestry populations. The study also confirmed in cell models that rs5051 T increases AGT transcription by up to 68.6% through altered transcription factor binding.

Gu et al. 2011⁵⁵ Gu et al. 2011
A-6G and A-20C Polymorphisms in the Angiotensinogen Promoter and Hypertension Risk in Chinese: A Meta-Analysis. PLoS One, 2011 pooled 15 studies comprising 3,442 hypertensive patients and 3,058 controls. Paradoxically, in Han Chinese populations where the T allele is very common (~83%), the dominant model showed the T (A at −6) allele was associated with lower hypertension risk (OR=0.71, 95%CI 0.57–0.87, p=0.001). Sex-specific analysis found protection was significant in women (OR=0.73) but not men. This apparently counterintuitive result likely reflects population-level confounding from linkage disequilibrium with other AGT haplotype variants, a pattern that differs between East Asian and European populations.

Chen et al. 2012⁶⁶ Chen et al. 2012
Promoter G-6A polymorphism associated with non-familial sick sinus syndrome. PLoS One, 2012 confirmed that the A allele at −6 produces higher AGT promoter transcriptional activity in luciferase assays and found that the G allele (lower AGT expression) was associated with sick sinus syndrome susceptibility — the complement of elevated-AGT effects on blood pressure.

Li et al. 2014⁷⁷ Li et al. 2014
AGT polymorphisms and essential hypertension in Northern Han Chinese. Angiology, 2014 found significantly different A-6G genotype distributions between 652 hypertensive patients and 780 controls (p<0.05) in a Chinese cohort, providing additional population-level evidence of the variant's role in essential hypertension susceptibility.

Practical Actions

Because rs5051 is tightly linked (r²=0.94) with rs699 (M235T), the two variants are almost always inherited together. Their combined effect on AGT expression and blood pressure is larger than either alone. Individuals carrying the T allele at rs5051 who also carry the G allele at rs699 have the highest angiotensinogen-driven blood pressure elevation.

For T allele carriers, the primary actionable implication is that a component of your blood pressure tends to be driven by genetically elevated angiotensinogen substrate supply to the RAAS. This means that RAAS-blocking medications — ACE inhibitors and angiotensin receptor blockers (ARBs) — target the precise upstream mechanism and may be particularly effective for blood pressure management in individuals with this genotype.

Dietary sodium restriction also exerts a larger effect on angiotensinogen-mediated blood pressure, since high sodium intake stimulates RAAS activity, compounding the elevated substrate supply.

Interactions

rs5051 and rs699 (AGT M235T) are almost universally co-inherited (r²=0.94) and function as a functional haplotype. rs5051 affects AGT transcription; rs699 changes the angiotensinogen protein sequence (Met235Thr), which independently affects angiotensinogen protein stability and plasma levels. The haplotype carrying rs5051-T + rs699-G produces the highest combined elevation in plasma angiotensinogen.

The RAAS as a whole is governed by several interacting variants: AGTR1 rs5186 (AT1 receptor, 3' UTR), ACE I/D rs4340 (ACE enzyme level), and CYP11B2 rs1799998 (aldosterone synthase). Individuals carrying multiple RAAS-elevating variants across these genes show compounding hypertension risk beyond the individual variant effects.

Every day your kidneys filter about 50 mg/dL of uric acid from the blood, but roughly 90% of that filtered urate gets reabsorbed — pulled back into the bloodstream before it can reach your urine. The single most important protein doing that reabsorption is URAT1¹¹ URAT1
Urate Transporter 1, encoded by SLC22A12 — the primary apical urate/anion exchanger in the renal proximal tubule. The rs505802 variant sits in the promoter region of SLC22A12 and influences how much URAT1 transporter your kidneys produce, directly setting the dial on how aggressively your body reclaims uric acid from the urine.

This makes rs505802 the third piece of a gout genetic panel alongside SLC2A9 (GLUT9, the basolateral urate transporter) and ABCG2 (the intestinal and renal secretory transporter). While SLC2A9 and ABCG2 variants alter the transporter protein itself, the SLC22A12 rs505802 variant operates upstream — it modulates the quantity of transporter produced rather than its per-molecule efficiency.

The Mechanism

rs505802 is located 2 kb upstream of SLC22A12 in the gene's regulatory region. The SLC22A12 promoter contains binding sites for HNF1α/β²² HNF1α/β
Hepatocyte nuclear factor 1 alpha and beta, transcription factors that drive kidney-specific URAT1 expression and estrogen response elements, both of which regulate tissue-specific expression. The C allele is associated with higher URAT1 expression and consequently greater renal urate reabsorption, while the T allele is associated with lower expression and more permissive urate excretion into the urine.

The variant is in near-perfect linkage disequilibrium (r² = 1 in Caucasians) with rs11231825 and rs11602903 in the SLC22A12 promoter region, meaning all three SNPs effectively tag the same functional haplotype. In African-ancestry populations, LD between these variants is lower, which is consistent with greater haplotype diversity.

URAT1 functions as an anion exchanger in the apical (luminal) membrane of proximal tubule cells: it swaps intracellular organic anions (lactate, nicotinate, pyrazinoate) for luminal urate, driving urate reabsorption. This is why URAT1 is the primary pharmacological target for uricosuric drugs — probenecid, lesinurad, benzbromarone, verinurad, and dotinurad all work by blocking this exchange, forcing more urate into the urine.

The Evidence

GWAS discovery and replication: The SLC22A12 locus was identified as genome-wide significant for serum uric acid in a meta-analysis of 28,141 Europeans (P = 2 × 10⁻⁹) Kolz et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 2009³³ Kolz et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 2009. Subsequent GWAS in Japanese (121,745 subjects, P = 1 × 10⁻³⁰⁰) and cross-ancestry cohorts (1,029,323 individuals, P = 5 × 10⁻³⁶⁰) confirmed rs505802 as one of the most robustly associated loci for serum urate in the human genome Cho et al., Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nature Communications, 2024⁴⁴ Cho et al., Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nature Communications, 2024.

Gout association: In 622 Han Chinese male gout cases and 917 controls, the T allele of rs505802 was protective against gout with an odds ratio of 0.747 (corrected P = 0.007), equivalent to a 25% reduction in gout risk per T allele Li et al., BMC Medical Genetics, 2015⁵⁵ Li et al., BMC Medical Genetics, 2015. A large PheWAS analysis confirmed the association: the T allele reduced gout risk with OR 0.86 (P = 1 × 10⁻⁹⁵) and was also associated with reduced gout medication use (P = 3 × 10⁻¹⁵) Verma et al., 2024⁶⁶ Verma et al., 2024.

Metabolic syndrome connection: In a study of 414 hypertensive patients, SLC22A12 promoter SNPs (including rs505802) explained 7% of BMI variation in Caucasians and were associated with metabolic syndrome (P = 0.033) Eraly et al., Kidney and Blood Pressure Research, 2012⁷⁷ Eraly et al., Kidney and Blood Pressure Research, 2012. This connects urate transport genetics to broader metabolic health beyond gout alone.

Effect size: The per-allele effect of rs505802 on serum urate is approximately −0.06 to −0.10 mg/dL per T allele across populations, with the largest effects observed in East Asian cohorts where the C allele is most prevalent. While smaller per-allele than SLC2A9, the population-level impact is substantial because of the high C allele frequency in non-European populations.

Practical Actions

The rs505802 genotype informs urate management through two key mechanisms: baseline risk stratification and pharmacological context. CC carriers have genetically elevated URAT1 expression, meaning their kidneys are programmed to reabsorb more uric acid. This creates a higher baseline that dietary purines, alcohol, and fructose push further upward.

For pharmacological context, CC carriers may respond more strongly to uricosuric drugs (probenecid, lesinurad, benzbromarone) because they have more URAT1 transporter to inhibit — this is the very target these drugs block. Conversely, TT carriers who already have lower URAT1 expression may derive less incremental benefit from uricosurics and might respond better to xanthine oxidase inhibitors (allopurinol, febuxostat) that reduce urate production instead.

Interactions

SLC2A9 (rs3733591) and ABCG2 (rs2231142): The three major urate transport genes — SLC22A12 (apical reabsorption via URAT1), SLC2A9 (basolateral reabsorption via GLUT9), and ABCG2 (apical secretion via BCRP) — operate at independent points in the renal urate handling pathway. Risk alleles at multiple loci compound additively. An individual carrying rs505802 CC, SLC2A9 rs3733591 CC, and ABCG2 rs2231142 TT has maximal urate reabsorption, minimal urate secretion, and substantially elevated gout risk beyond any single variant alone.

Estrogen and sex-specific effects: The SLC22A12 promoter contains estrogen response elements, and URAT1 expression is modulated by estrogen status. Pre-menopausal women have lower urate levels in part because estrogen suppresses URAT1 expression; post-menopausal women lose this protection. The rs505802 C allele effect may be amplified after menopause as estrogen-mediated transcriptional suppression of SLC22A12 is lost.

Uricosuric drug response: Probenecid, lesinurad, and benzbromarone all inhibit URAT1 directly. Individuals with higher URAT1 expression (CC genotype) have a larger pharmacological target for these drugs and may show a more robust uricosuric response. This pharmacogenomic relationship has not yet been confirmed in prospective clinical trials but is mechanistically well-supported.